Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

48 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial.
Borchmann P, Ferdinandus J, Schneider G, Moccia A, Greil R, Hertzberg M, Schaub V, Hüttmann A, Keil F, Dierlamm J, Hänel M, Novak U, Meissner J, Zimmermann A, Mathas S, Zijlstra JM, Fosså A, Viardot A, Hertenstein B, Martin S, Giri P, Scholl S, Topp MS, Jung W, Vucinic V, Beck HJ, Kerkhoff A, Unger B, Rank A, Schroers R, Zum Büschenfelde CM, de Wit M, Trautmann-Grill K, Kamper P, Molin D, Kreissl S, Kaul H, von Tresckow B, Borchmann S, Behringer K, Fuchs M, Rosenwald A, Klapper W, Eich HT, Baues C, Zomas A, Hallek M, Dietlein M, Kobe C, Diehl V; German Hodgkin Study Group; Swiss Group for Clinical Cancer Research; Arbeitsgemeinschaft Medikamentöse Tumortherapie; Nordic Lymphoma Group; Australasian Leukaemia and Lymphoma Group. Borchmann P, et al. Among authors: ferdinandus j. Lancet. 2024 Jul 27;404(10450):341-352. doi: 10.1016/S0140-6736(24)01315-1. Epub 2024 Jul 3. Lancet. 2024. PMID: 38971175 Free article. Clinical Trial.
Managing patient flows in radiation oncology during the COVID-19 pandemic : Reworking existing treatment designs to prevent infections at a German hot spot area University Hospital.
Akuamoa-Boateng D, Wegen S, Ferdinandus J, Marksteder R, Baues C, Marnitz S. Akuamoa-Boateng D, et al. Among authors: ferdinandus j. Strahlenther Onkol. 2020 Dec;196(12):1080-1085. doi: 10.1007/s00066-020-01698-6. Epub 2020 Oct 29. Strahlenther Onkol. 2020. PMID: 33123776 Free PMC article.
Correction to: Managing patient flows in radiation oncology during the COVID-19 pandemic : Reworking existing treatment designs to prevent infections at a German hot spot area University Hospital.
Akuamoa-Boateng D, Wegen S, Ferdinandus J, Marksteder R, Baues C, Marnitz S. Akuamoa-Boateng D, et al. Among authors: ferdinandus j. Strahlenther Onkol. 2021 Feb;197(2):158. doi: 10.1007/s00066-020-01724-7. Strahlenther Onkol. 2021. PMID: 33324998 Free PMC article. No abstract available.
Interim FDG-PET analysis to identify patients with aggressive non-Hodgkin lymphoma who benefit from treatment intensification: a post-hoc analysis of the PETAL trial.
Seifert R, Kersting D, Rischpler C, Sandach P, Ferdinandus J, Fendler WP, Rahbar K, Weckesser M, Umutlu L, Hanoun C, Hüttmann A, Reinhardt HC, von Tresckow B, Herrmann K, Dührsen U, Schäfers M. Seifert R, et al. Among authors: ferdinandus j. Leukemia. 2022 Dec;36(12):2845-2852. doi: 10.1038/s41375-022-01713-y. Epub 2022 Oct 14. Leukemia. 2022. PMID: 36241697 Free PMC article. Clinical Trial.
Prognostic value of baseline metabolic tumor volume (MTV) for forecasting chemotherapy outcome in early-stage unfavorable Hodgkin lymphoma: Data from the phase III HD17 trial.
van Heek L, Weindler J, Gorniak C, Kaul H, Müller H, Mettler J, Baues C, Fuchs M, Borchmann P, Ferdinandus J, Dietlein M, Voltin CA, Kobe C, Roth KS. van Heek L, et al. Among authors: ferdinandus j. Eur J Haematol. 2023 Dec;111(6):881-887. doi: 10.1111/ejh.14093. Epub 2023 Aug 29. Eur J Haematol. 2023. PMID: 37644732
Patterns of PET-positive residual tissue at interim restaging and risk of treatment failure in advanced-stage Hodgkin's lymphoma: an analysis of the randomized phase III HD18 trial by the German Hodgkin Study Group.
Ferdinandus J, van Heek L, Roth K, Dietlein M, Eich HT, Baues C, Borchmann P, Kobe C. Ferdinandus J, et al. Eur J Nucl Med Mol Imaging. 2024 Jan;51(2):490-495. doi: 10.1007/s00259-023-06431-w. Epub 2023 Sep 22. Eur J Nucl Med Mol Imaging. 2024. PMID: 37735258 Free PMC article. Clinical Trial.
Impact of individualized treatment on recovery from fatigue and return to work in survivors of advanced-stage Hodgkin's lymphoma: results from the randomized international GHSG HD18 trial.
Ferdinandus J, Müller H, Damaschin C, Jacob AS, Meissner J, Krasniqi F, Mey U, Schöndube D, Thiemer J, Mathas S, Zijlstra J, Greil R, Feuring-Buske M, Markova J, Rüffer JU, Kobe C, Eich HT, Baues C, Fuchs M, Borchmann P, Behringer K. Ferdinandus J, et al. Ann Oncol. 2024 Mar;35(3):276-284. doi: 10.1016/j.annonc.2023.11.014. Epub 2023 Dec 5. Ann Oncol. 2024. PMID: 38061428 Free article.
[No title available]
[No authors listed] [No authors listed] PMID: 39112144
Circulating Tumor DNA Sequencing for Biologic Classification and Individualized Risk Stratification in Patients With Hodgkin Lymphoma.
Heger JM, Mammadova L, Mattlener J, Sobesky S, Cirillo M, Altmüller J, Kirst E, Reinke S, Klapper W, Bröckelmann PJ, Ferdinandus J, Kaul H, Schneider G, Schneider J, Schleifenbaum JK, Ullrich RT, Freihammer M, Awerkiew S, Lohmann M, Klein F, Nürnberg P, Hallek M, Rossi D, Mauz-Körholz C, Gattenlöhner S, Bräuninger A, Borchmann P, von Tresckow B, Borchmann S. Heger JM, et al. Among authors: ferdinandus j. J Clin Oncol. 2024 Sep 30:JCO2301867. doi: 10.1200/JCO.23.01867. Online ahead of print. J Clin Oncol. 2024. PMID: 39348625
48 results